Ebrasodebart Biosimilar – Anti-IGFBP-3R mAb – Research Grade from ProteoGenix; catalogue PX-TA2188; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Ebrasodebart Biosimilar – Anti-IGFBP-3R mAb – Research Grade is a novel therapeutic antibody that specifically targets insulin-like growth factor binding protein-3 receptor (IGFBP-3R). This biosimilar is designed to mimic the structure and function of the original Ebrasodebart antibody, which has shown promising results in preclinical studies for the treatment of various diseases.
Ebrasodebart Biosimilar is a monoclonal antibody (mAb) that is produced through recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to IGFBP-3R, while the Fc region is involved in effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
IGFBP-3R is a cell surface receptor that binds to insulin-like growth factor binding protein-3 (IGFBP-3) and regulates the activity of insulin-like growth factor (IGF). Overexpression of IGFBP-3R has been linked to various diseases, including cancer, diabetes, and cardiovascular diseases. Ebrasodebart Biosimilar binds to IGFBP-3R with high affinity, preventing the interaction between IGFBP-3 and IGF. This disrupts the downstream signaling pathways involved in cell proliferation, survival, and migration, leading to inhibition of disease progression.
Ebrasodebart Biosimilar has shown potential in the treatment of various diseases, including:
Ebrasodebart Biosimilar – Anti-IGFBP-3R mAb – Research Grade is currently in the preclinical stage of development. Extensive research is being conducted to evaluate its safety and efficacy in various disease models. This research grade biosimilar is not yet approved for clinical use, but it shows great potential for future therapeutic applications.
Ebrasodebart Biosimilar – Anti-IGFBP-3R mAb – Research Grade is a promising therapeutic antibody that targets IGFBP-3R and has potential applications in cancer, diabetes,
ProteoGenix catalogue number PX-TA2188. For research use only.
Target: Ebrasodebart Biosimilar – Anti-IGFBP-3R mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4; Applications: WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Ebrasodebart Biosimilar – Anti-IGFBP-3R mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
